This analysis examines the historical and forecast performance for Daiichi Sankyo in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Scope
Highlights of this title
Key reasons to purchase this title
- Benchmark Daiichi Sankyos performance against key rivals in the ethical pharmaceutical sector
- See how the continued success of Daiichis olmesartan antihypertensives franchise (Benicar, Benicar HCT and Azor) is central to the companys outlook
- Evaluate the prospects of the companys key pipeline candidate, prasugrel, which is being co-developed with Eli Lilly
